| 3.42 0.18 (5.56%) | 04-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.69 | 1-year : | 7 |
| Resists | First : | 4.87 | Second : | 6 |
| Pivot price | 3.68  |
|||
| Supports | First : | 3.06 | Second : | 2.54 |
| MAs | MA(5) : | 3.24 |
MA(20) : | 3.85 |
| MA(100) : | 3.85 |
MA(250) : | 2.62 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 7.7 |
D(3) : | 3.8 |
| RSI | RSI(14): 45.1 |
|||
| 52-week | High : | 9.77 | Low : | 0.17 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TPST ] has closed above bottom band by 37.5%. Bollinger Bands are 63.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 16 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.48 - 3.49 | 3.49 - 3.51 |
| Low: | 3.2 - 3.22 | 3.22 - 3.24 |
| Close: | 3.39 - 3.42 | 3.42 - 3.45 |
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
Wed, 17 Apr 2024
Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch (NASDAQ:TPST) - Seeking Alpha
Wed, 17 Apr 2024
Bears are Losing Control Over Tempest Therapeutics, Inc. (TPST), Here's Why It's a 'Buy' Now - Yahoo Movies UK
Sat, 13 Apr 2024
Tempest Therapeutics, Inc. (NASDAQ:TPST) Short Interest Up 26.5% in March - MarketBeat
Tue, 09 Apr 2024
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting - Yahoo Finance
Thu, 04 Apr 2024
Tempest Therapeutics moves TPST-1120 into phase 3 trial By Investing.com - Investing.com
Mon, 01 Apr 2024
Is Tempest Therapeutics Inc (TPST) a Stock to Watch After Gaining 8.52% This Week? - InvestorsObserver
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 22 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 3.1 (%) |
| Held by Institutions | 29.2 (%) |
| Shares Short | 970 (K) |
| Shares Short P.Month | 717 (K) |
| EPS | -1.91 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.21 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -37.4 % |
| Return on Equity (ttm) | -131.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -27 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | -1.8 |
| PEG Ratio | 0 |
| Price to Book value | 2.82 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.78 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|